ZyVersa Therapeutics, Inc. (ZVSA) Financials
ZVSA Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Dec. 31, 2025 | 347.9 million | 12.7 billion |
| Sept. 30, 2025 | 1.0 million | 12.8 million |
| June 30, 2025 | 19.6 million | 13.5 million |
| March 31, 2025 | 21.0 million | 12.9 million |
ZVSA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Dec. 31, 2025 | -413.7 million | 17.4 million |
| Sept. 30, 2025 | -1.4 billion | 74.0 million |
| June 30, 2025 | -1.5 billion | 59.2 million |
| March 31, 2025 | -1.8 billion | 72.3 million |
ZVSA Net Income
No data available :(
ZVSA Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Dec. 31, 2025 | 101.8 million | - | - |
| Sept. 30, 2025 | 527978 | - | - |
| June 30, 2025 | 72086 | - | - |
| March 31, 2025 | 1.6 million | - | - |
ZVSA Shares Outstanding
ZVSA Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Dec. 31, 2025 | - | 79.2 million | 472.6 million | - |
| Sept. 30, 2025 | - | 365.1 million | 1.7 billion | - |
| June 30, 2025 | - | 409.9 million | 1.6 billion | - |
| March 31, 2025 | - | 258.9 million | 1.9 billion | - |
ZVSA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Dec. 31, 2025 | - | - |
| Sept. 30, 2025 | - | - |
| June 30, 2025 | - | - |
| March 31, 2025 | - | - |
ZVSA
Price: $0.19
52 week price:
Earnings Per Share: -3.32 USD
P/E Ratio: -0.07
Exchange: OQB
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 1.6 million